GC Pharma shares lysosomal storage disease drug development updates at WORLD Symposium 2026
GC Pharma said Tuesday it presented updates on its lysosomal storage disease (LSD) drug programs at WORLD Symposium 2026, held Feb. 2-6 in San Diego.
WORLD Symposium is an international forum where LSD specialists share the latest research and discuss improved treatments. GC Pharma presented a poster on preclinical results for GC1130A, a candidate treatment for Sanfilippo syndrome type A (MPSIIIA). The company is developing the drug for direct delivery into the brain’s ventricles (ICV) to improve efficacy.
In preclinical animal studies, heparan sulfate levels in the brains of disease-model animals given GC1130A fell significantly, and researchers observed reduced brain inflammation and improved cognitive ability. GC1130A is in Phase 1 trials in the United States and South Korea and has received fast-track designation from the U.S. Food and Drug Administration. The company plans to complete Phase 1 this year and aims to commercialize the drug before 2030.
GC Pharma also joined a global investigator meeting for HM15421/GC1134A, a Fabry disease treatment candidate, sharing safety indicators and preliminary pharmacokinetics and pharmacodynamics data from cohort 1 and discussing clinical strategy. With enrollment for cohort 1 complete, the company plans to begin registering cohort 2 participants in the second quarter.
Dongkook Pharmaceutical asks Korean IP office for continued cooperation in anti-counterfeit efforts
Dongkook Pharmaceutical said Tuesday it held a meeting Feb. 9 with the Korean Intellectual Property Office at its headquarters in Seoul to discuss preventing counterfeit distribution and protecting consumers for its dermacosmetics brand Centellian24.
The two sides shared information on the spread of counterfeit goods, particularly through domestic online channels and overseas distribution, and discussed cooperation to crack down on counterfeits and block distribution. They agreed the issue has significant implications for consumer safety and brand trust and said continued cooperation is needed.
Dongkook Pharmaceutical said counterfeit versions of key Centellian24 products, including Madeca Cream and Melacapture Ampoule, are being sold in packaging similar to genuine items. The company said counterfeit products can be difficult to verify for ingredients and may pose a high risk of serious side effects if applied to the skin.
Kwangdong Pharmaceutical says Cheonghyeonghwan tops 160 billion won in cumulative sales
Kwangdong Pharmaceutical said Tuesday that cumulative sales of Kwangdong Cheonghyeonghwan surpassed 160 billion won from its 2019 launch through 2025.
The pill-form product uses agarwood and deer antler velvet as main ingredients. The company said cumulative sales volume reached about 27 million pills, based on 30 pills per box, and the repurchase rate was 99.8%.
Kwangdong Pharmaceutical said it runs a quality-control system covering the full process from ingredient selection to manufacturing. It said it tests for about 540 types of harmful substances, including pesticide residues, and produces the product through a 45-step process at facilities certified under the Hazard Analysis and Critical Control Points standard, from raw-material intake to finished-product inspection. The company said it has introduced automation in the filling and packaging stage.
ABL Bio publishes review paper on 4-1BB antibodies in international journal
The paper, titled “Expanding the horizon of cancer therapy with next-generation 4-1BB antibodies: a review of molecular and clinical strategies to maximize efficacy and ensure safety,” was released online Feb. 6.
According to the paper, 4-1BB bispecific antibodies showed improved anticancer efficacy and a favorable safety profile compared with conventional monoclonal antibodies. It described an approach that limits T-cell activation through 4-1BB signaling to the tumor microenvironment where cancer cells are present, as a way to address limitations seen with earlier 4-1BB monoclonal antibodies urelumab and utomilumab.
The paper said 4-1BB may also support longer-lasting anticancer effects and could play an important role in future combination therapies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.